WO2002102394A2 - Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport - Google Patents
Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport Download PDFInfo
- Publication number
- WO2002102394A2 WO2002102394A2 PCT/CA2002/000843 CA0200843W WO02102394A2 WO 2002102394 A2 WO2002102394 A2 WO 2002102394A2 CA 0200843 W CA0200843 W CA 0200843W WO 02102394 A2 WO02102394 A2 WO 02102394A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- krill
- marine
- composition
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport.
- This invention relates to multi-therapeutic extracts derived from krill and/or marine, which can prevent and/or treat several diseases.
- Krill is the common name for small, shrimp-like crustaceans, however not shrimp, that swarm in dense shoals, especially in Antarctic waters. It is one of the most important food source for fish, some kind of birds and especially for baleen whales as being an important source of protein. Krill is also a good source of omega-3 fatty acid, which are well known for their health benefits.
- krill and/or marine enzymes for the treatment of a great variety of diseases in human and animals such as infections, inflammations, cancers, HIV/AIDS, pain, polyps, warts, hemorrhoids, plaque, wrinkles, thin hairs, allergic itch, anti-adhesion, eye disease, acne, cystic fibrosis and immune disorders including autoimmune disease and cancer.
- krill and/or marine oil may be used for the treatment of autoimmune murine lupus and other autoimmune diseases and can also be used for treating cardiovascular diseases.
- the krill and/or marine oil used for these treatments has only conserved its omega-3 fatty acids as active ingredients, which is a very small part of all the active ingredients of the krill and/or marine itself. This fact reduces the potential of the krill and/or marine oil as a treatment for these diseases.
- a method of prevention, therapy and/or treatment of several disease comprising the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
- the krill and/or marine oil is obtained from a process comprising the steps of:
- the krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine,
- Phosphatidylethanola mine, Sphingomyelin, a-tocopherol, all-trans retinol, Astaxanthin and flavonoid.
- the krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Linolenic acid, Alpha-linolenic acid, Linoleic acid, Arachidonic acid, Oleic acid, palmitic acid, palmitoleic acid, stearic acid, nervonic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine,
- Phosphatidylethanolamine Sphingomyelin, Cholesterol, Triglycerides, Monoglycerides, a-tocopherol, all-trans retinol, Astaxanthin, Canthaxanthin, ⁇ -carotene, flavonoid, Zinc, Selenium, sodium, potassium and calcium.
- the krill and/or marine oil comprises Eicosapentanoic acid, Docosahexanoic acid, Linolenic acid, Alpha-linolenic acid, Linoleic acid, Arachidonic acid, Oleic acid, palmitic acid, palmitoleic acid, stearic acid, Phosphatidylcholine, Phosphatidylinositol, Phosphatidylserine, Phosphatidylethanolamine, Sphingomyelin, Cholesterol, Triglycerides, Monoglycerides, a-tocopherol, all-trans retinol, Astaxanthin, Canthaxanthin, ⁇ -carotene, Zinc and Selenium.
- the diseases that can be treated and/or prevented by the method of the present invention are cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport enhancement.
- compositions for the treatment and/or prevention and/or therapy of the previously mentioned diseases comprising a therapeutically effective amount of krill and/or marine oil in association with a pharmaceutically acceptable carrier.
- krill and/or marine oil for the treatment and/or prevention and/or therapy of the previously mentioned diseases.
- krill and/or marine extract for prevention and/or treatment and/or therapy of several diseases.
- a multi-therapeutic oil extract free of enzyme is derived from krill and/or marine, found in any marine environment around the world, for example, the Antarctic ocean (euphasia superba), the Pacific ocean (euphasia pacifica), the Atlantic ocean, the Indian ocean, in particular coastal regions of Mauritius Island and/or Reunion Island of Madagascar, Canadian West Coast, Japanese Coast, St-Lawrence Gulf and Fundy Bay, and this oil extract is a free fatty acid lipid fraction.
- the extraction process can be described as the following:
- an organic solvent which can be alcohol, preferably ethanol, isopropanol or t-butanol, or esters of acetic acid, preferably ethyl acetate. This in order to extract the remaining soluble lipid fraction from the solid phase;
- step (f) Recovering a lipid rich fraction from the liquid phase obtained at step (e) by evaporation of the solvent present in the liquid phase.
- the active components of the enzyme-free krill and/or marine oil extract are: lipids i) Omega-3: i. Eicosapentanoic acid: >8g/100g ii. Docosahexanoic acid: >2g/100g iii. Linolenic acid: >0.10g/100g iv. Alpha-linolenic acid: >0.3g/100g
- the Omega-3 are found in more than 30g/100g.
- Omega-6 i. Linoleic acid: >0.9g/100g ii.
- Arachidonic acid ⁇ 0.45g/100g, preferably ⁇ 0.6g/100g iii)
- Omega-9 i.
- Oleic acid >5g/100g iv) palmitic acid: >10g/100g v) palmitoleic acid: 0.08g/100g vi) stearic acid: > 0.5g/100g
- Triglycerides ⁇ 55g/100g
- the neutral lipids of the krill and/or marine extract also comprises:
- vitamin E >1.0 IU/100g all-trans retinol (vitamin A): >1500 IU/100g ⁇ -carotene: > 3000 ⁇ g/100 ml Pigments
- Astaxanthin >20 mg/100g
- Canthaxanthin > 2 mg/100g
- the krill and/or marine extract also comprises:
- Flavonoids >0.5mg/100g
- the extract contains less than 25 ppm of solvent residue from the extraction process.
- the oil has the following stability indexes:
- Oil Stability index ⁇ 0.1 after 50 hours at 97.8°C
- Krill and/or marine oil has been shown to decrease cholesterol in vivo. It also inhibits platelet adhesion and plaque formation and reduces vascular endothelial inflammation in a patient. It can offer hypertension prophylaxis. It prevents oxidation of low-density lipoprotein. It may have an inhibitory effect on the secretion of VLDL due to increased intracellular degradation of apo B-100. It also offers a post-myocardial infarction prophylaxis because of its ability to decrease Clll apolipoprotein B, to decrease Clll non-apolipoprotein B lipoproteins and to increase antithrombin III levels.
- Krill and/or marine oil is suitable for prophylactic usage against cardiovascular disease in human where cardiovascular disease relates to coronary artery disease, hyperlipidemia, hypertension, ischemic disease (relating to angina, myocardial infarction, cerebral ischemia, shock without clinical or laboratory evidence of ischemia, arrhythmia)
- cardiovascular disease relates to coronary artery disease, hyperlipidemia, hypertension, ischemic disease (relating to angina, myocardial infarction, cerebral ischemia, shock without clinical or laboratory evidence of ischemia, arrhythmia)
- the patients were tested for LDL, HDL, Triglycerides, vital signs, CBC, SGOT/SGPT, ⁇ -GT, ALP, Urea, Creatine, Glucose, K + , Na ⁇ Ca 2+ and total indirect bilirubin cholesterol before treatment and also at 2 months.
- Table 1 is showing the results obtained from the previously described tests: Table 1 Paired Samples Test
- Krill and/or marine oil offers symptomatic relief for Arthritis where arthritis relates to adult arthritis, Still's disease, polyarticular or pauciarticular juvenile rheumatoid arthritis, rheumatoid arthritis, osteoarthritis because it has been shown that it provides a clinical improvement in decreasing the number of tender joints and of analgesics consumed daily by decreasing the production of lnterleukin-8 and lnterleukin-1 in human patients. Patients with a bleeding tendency or severe psychiatric disease were excluded from the study.
- the recommended dosage varies between 1 and 4.8 grams of pure krill extract per day.
- the inclusion criteria for the study are being aged between 50 and 65 years, both genders being admissible, having a clinical diagnosis of primary osteoarthritis (mild to moderate) 6 to 12 months prior to study enrollment including pain and stiffness, radiographic confirmation of illness prior to enrollment. It also include evidence of measurable symptoms of OA for at least 3 months prior to study enrollment requiring the use of acetaminophen, anti-inflammatory agents or opioid analgesics. Patients were asked to stop the use of all "pain-killers" the week prior to initiation of the trial for wash-out purposes.
- the Exclusion criteria were a severe osteoarthritis, unavoidable sustained use of NSAID's, aspirin or other medicines for anti-inflammatory use, use of topical analgesics within 4 weeks of randomization visit, steroid injection into either knee within past 3 months, initiation of physical therapy or muscle conditioning within 3 months, seafood allergies, use of anticoagulants or salicylates, alcohol consumption exceeding 3 mixed drinks per day, concurrent medical/arthritic disease that could confound or interfere with the evaluation of pain, prior surgery (including arthroscopy) of either knee, a known "secondary" cause of osteoarthritis.
- Evaluation was based on daily dose of NSAIDs and/or analgesics and/or SAARDs, number of painful joints, number or swollen joints, duration of morning stiffness, visual analog scale (0-100) WOMACscale and SF36. Preliminary results have been obtained after 2 months. The number of NSAIDs and/or analgesics and/or SAARDs required for daily functioning has been recorded at initiation and at 2 months after initiation.
- Results shown at Table 2 demonstrate the effect of an uptake of krill extract on the relief of arthritis.
- Krill and/or marine oil has been shown to be a skin cancer prophylactic because of its retinol anti-carcinogenic effect, Astaxanthin anti-carcinogenic effect and its phopholipid anti-carcinogenic effect.
- nude mice preferably on C57BL6 Nude Congenic Mice - B6NU-T (heterozygotes) because of their proven susceptibility to skin cancer.
- mice were formed as follows: 48 fish oil: 16 with oral supplementation (po) 16 with local application, 16 with po and local application; 48 krill and/or marine oil: 16 with po, 16 with local application, 16 with po and local application.
- the test was conducted as a randomized blind controlled trial (statistical significance p ⁇ 0.05). Half of the mice have been treated orally or topically or both with oil containing 100% by weight krill and/or marine oil and the other half have been treated the same way with fish oil.
- Nutrition was fat-free chow for the first week and was modified accordingly with the assigned group as described below for the following 2- 20 weeks in the quantity of 1 ml of oil per day.
- mice were divided in six groups as follows:
- Group A fat-free chow with supplementation of fish oil (20% of total calories)
- Group B fat-free chow (100% of calories) + local application of fish oil 2 times per day
- Group C fat free chow with supplementation of fish oil (20% of total calories) + local application of soy oil 2 times per day
- Group D fat-free chow with supplementation of krill and/or marine oil (20% of total calories)
- Group E fat free chow (100% of calories) + local application of krill and/or marine oil 2 times per day
- Group F fat-free chow with supplementation or krill and/or marine oil (20% of total calories) + local application of krill and/or marine oil 2 times per day
- mice had been submitted to UVB radiation using a fluorescent test lamp, emission spectrum 270-400 nm during weeks 2-20.
- the essay were performed during 30 minutes of UVB exposure per day and the test lamp was at a distance of 30 cm from the mice.
- mice were anesthetized with ether and sacrificed. Skin was examined blind by pathologists for signs of carcinogenesis.
- Tables 3-8) are showing the results obtained about the incidence of cancer when ultra-violet radiations are administered to mice's skin during 5 weeks.
- Krill and/or marine oil enhances transdermal transportation as a substrate for dermatological topical therapeutic applications. It may be used in dermatological treatments via creams, ointments, gels, lotions and oils. It may also be used in various therapeutic applications such as relating to anesthesic, corticosteroids, anti-inflammatory, antibiotic and ketolytic functions.
- Krill and/or marine oil can be used to enhance transdermal transportation as a substrate for dermatological topical cosmetic applications where cosmetic applications relate to skin hydration, anti- wrinkle, keratolytics, peeling and mask via creams, ointments, gels, lotions or oils.
- Table 9 shows results obtained on skin hydration following the method previously described.
- krill extract is useful for anti-wrinkle treatment.
- the mechanism of all-trans retinol, which is included in the krill oil, as an anti-wrinkle works as follows: - Regeneration and distinctive anti-inflammatory effects
- Table 10 shows results obtained from the use of krill oil to reduce the pain and mood changes associated with premenstrual syndrome in women.
- Krill oil extract was administered to 7 women during 2 months. The women were taking 6 capsules of krill extract per day, each capsule containing 800 mg of krill oil.
- a recommended daily intake of krill oil is of about 1 to 4.8 grams. All participants were advised to continue with their usual nutrition habits and to refrain from initiating any restrictions in their diet. No serious side effects were reported.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Marine Sciences & Fisheries (AREA)
- Insects & Arthropods (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60230759T DE60230759D1 (en) | 2001-06-18 | 2002-06-07 | KRILLEXTRAKTS FOR THE PREVENTION AND / OR TREATMENT OF CARDIOVASCULAR DISEASES |
EP02734945A EP1406641B1 (en) | 2001-06-18 | 2002-06-07 | Krill extracts for prevention and/or treatment of cardiovascular diseases |
DK02734945T DK1406641T3 (en) | 2001-06-18 | 2002-06-07 | Curly extracts for the prevention and / or treatment of cardiovascular diseases |
CA2449898A CA2449898C (en) | 2001-06-18 | 2002-06-07 | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
JP2003504980A JP5135568B2 (en) | 2001-06-18 | 2002-06-07 | Krill and / or marine organism extracts for prevention and / or treatment of cardiovascular disease, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal delivery |
US10/481,040 US20040241249A1 (en) | 2001-06-18 | 2002-06-07 | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport |
NO20035618A NO332690B1 (en) | 2001-06-18 | 2003-12-16 | Use of krill oil for the production of a pharmaceutical preparation for the prevention of hypercholesterolemia or hypertension. |
US11/640,235 US8057825B2 (en) | 2001-06-18 | 2006-12-18 | Krill extracts for treatment of cardiovascular diseases |
US13/216,694 US20110305771A1 (en) | 2001-06-18 | 2011-08-24 | Krill Extracts for Treatment of Cardiovascular Diseases |
US14/152,603 US20140199414A1 (en) | 2001-06-18 | 2014-01-10 | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
US15/267,988 US20170224742A1 (en) | 2001-06-18 | 2016-09-16 | Phospholipid-containing marine extracts for treatment of cardiovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29838301P | 2001-06-18 | 2001-06-18 | |
US60/298,383 | 2001-06-18 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10481040 A-371-Of-International | 2002-06-07 | ||
US10/481,040 A-371-Of-International US20040241249A1 (en) | 2001-06-18 | 2002-06-07 | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport |
US11/640,235 Division US8057825B2 (en) | 2001-06-18 | 2006-12-18 | Krill extracts for treatment of cardiovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002102394A2 true WO2002102394A2 (en) | 2002-12-27 |
WO2002102394A3 WO2002102394A3 (en) | 2003-04-10 |
Family
ID=23150259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000843 WO2002102394A2 (en) | 2001-06-18 | 2002-06-07 | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport |
Country Status (14)
Country | Link |
---|---|
US (5) | US20040241249A1 (en) |
EP (2) | EP1406641B1 (en) |
JP (4) | JP5135568B2 (en) |
CN (2) | CN102319266B (en) |
AT (2) | ATE419858T1 (en) |
CA (1) | CA2449898C (en) |
CY (1) | CY1108986T1 (en) |
DE (1) | DE60230759D1 (en) |
DK (2) | DK1997498T3 (en) |
ES (2) | ES2386841T3 (en) |
HK (2) | HK1126957A1 (en) |
NO (1) | NO332690B1 (en) |
PT (1) | PT1406641E (en) |
WO (1) | WO2002102394A2 (en) |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064820A2 (en) * | 2003-01-20 | 2004-08-05 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
WO2004112776A2 (en) | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
FR2859380A1 (en) * | 2003-09-05 | 2005-03-11 | Phythea | Orally administered cosmetic skin treatment composition, effective in improving moisturization, texture and suppleness, containing synergistic combination of krill, kiwi fruit seed and cold sea fish oils |
WO2005039559A1 (en) * | 2003-10-29 | 2005-05-06 | Suntory Limited | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
EP1727882A1 (en) * | 2004-02-06 | 2006-12-06 | Adrien Beaudoin | Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof |
EP1736149A3 (en) * | 2005-06-23 | 2007-02-21 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin-containing agent for lowering neutral fat concentration in blood |
WO2007045407A2 (en) * | 2005-10-18 | 2007-04-26 | Artmed S.R.L. | Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma |
WO2007080515A1 (en) * | 2006-01-13 | 2007-07-19 | Aker Biomarine Asa | Thrombosis preventing krill extract |
JP2007529507A (en) * | 2004-03-16 | 2007-10-25 | ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | Methods of using sphingolipids in the treatment and prevention of type 2 diabetes, insulin resistance and metabolic syndrome |
WO2008117062A1 (en) * | 2007-03-28 | 2008-10-02 | Aker Biomarine Asa | Bioeffective krill oil compositions |
WO2008139261A2 (en) * | 2006-11-03 | 2008-11-20 | Pronova Biopharma Norge As | Omega-3 lipid compound |
US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
WO2010136900A2 (en) | 2009-05-28 | 2010-12-02 | Aker Biomarine Asa | Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders |
US7906488B2 (en) | 2004-11-30 | 2011-03-15 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
WO2011050474A1 (en) | 2009-10-29 | 2011-05-05 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
WO2011062953A1 (en) * | 2009-11-17 | 2011-05-26 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Use of eggshell membrane formulations to alleviate joint pain |
US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US8202907B2 (en) | 2004-09-17 | 2012-06-19 | Suntory Holdings Limited | Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders |
US8278351B2 (en) | 2001-07-27 | 2012-10-02 | Neptune Technologies & Bioressources, Inc. | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
US8383677B2 (en) | 2006-12-28 | 2013-02-26 | Suntory Holdings Limited | Nerve-regenerating agent |
KR101249707B1 (en) | 2003-10-28 | 2013-04-05 | 에모리 유니버시티 | Dialysates and methods and systems related thereto |
WO2013102792A2 (en) | 2012-01-03 | 2013-07-11 | Olympic Seafood As | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
AU2011213836B2 (en) * | 2007-03-28 | 2013-11-14 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US8609157B2 (en) | 2009-10-30 | 2013-12-17 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
US8691297B2 (en) | 2010-09-01 | 2014-04-08 | Nippon Suisan Kaisha, Ltd. | Alcoholic injury mitigating agent |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
US8703172B2 (en) | 2003-01-20 | 2014-04-22 | Nederlandse Organizatie voor Toegepastnatuurwetenschappelijk Onderzoek TNO | Sphingolipids for improvement of the composition of the intestinal flora |
AU2014100736B4 (en) * | 2007-03-28 | 2014-09-18 | Aker Biomarine Antarctic As | Processes and products thereof |
US8846604B2 (en) | 2011-09-02 | 2014-09-30 | Artic Nutrition AS | Lipid compositions with high DHA content |
WO2014184655A1 (en) | 2013-02-07 | 2014-11-20 | Olympic Seafood As | Methods for using crustacean phospholipid-peptide-protein complexes |
US9050309B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
AU2013205515B2 (en) * | 2001-07-27 | 2015-07-02 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
US9167832B2 (en) | 2008-09-12 | 2015-10-27 | Emerald Fisheries As | Low flouride crustacean concentrated hydrolysate fraction compositions |
US9168241B2 (en) | 2005-06-30 | 2015-10-27 | Suntory Holdings Limited | Compositions ameliorating a reduced diurnal activity and/or depressive symptoms |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
EP3181129A1 (en) * | 2015-12-15 | 2017-06-21 | Wolfgang Braun | Composition for the treatment of premenstrual syndrome |
US9867856B2 (en) | 2014-01-10 | 2018-01-16 | Aker Biomarine Antarctic As | Phospholipid compositions and their preparation |
US10456412B2 (en) | 2015-02-11 | 2019-10-29 | Aker Biomarine Antarctic As | Lipid extraction processes |
US10499673B2 (en) | 2008-09-12 | 2019-12-10 | Rimfrost Technologies As | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
WO2020006444A1 (en) * | 2018-06-28 | 2020-01-02 | Marizyme Biotech | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
US10704011B2 (en) | 2013-06-14 | 2020-07-07 | Aker Biomarine Antarctic As | Lipid extraction processes |
US10744146B2 (en) | 2001-08-02 | 2020-08-18 | Suntory Holdings Limited | Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
US10864223B2 (en) | 2015-02-11 | 2020-12-15 | Aker Biomarine Antarctic As | Lipid compositions |
CN112315984A (en) * | 2020-09-09 | 2021-02-05 | 山东省科学院生物研究所 | Application of marine-derived phospholipid in promoting angiogenesis |
IT202000003964A1 (en) * | 2020-02-26 | 2021-08-26 | Umberto Cornelli | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSMENORREA AND / OR PREMESTRUAL SYNDROME |
US20220265291A9 (en) * | 2018-06-28 | 2022-08-25 | Marizyme, Inc. | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
GB2612442A (en) * | 2021-09-28 | 2023-05-03 | L Shepherd Samuel | Tetraterpenes for use in cancer therapy |
US11654163B2 (en) | 2017-12-22 | 2023-05-23 | Pharmalink International Limited | Lipid combinations |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070213298A1 (en) * | 2006-02-07 | 2007-09-13 | Universitetet I Oslo | Omega 3 |
PL2046312T3 (en) * | 2006-07-14 | 2021-02-08 | Kaydence Pharma As | Pharmaceutical and nutraceutical products comprising vitamin k2 |
KR101343290B1 (en) * | 2007-08-29 | 2013-12-18 | 에이커 바이오마린 에이에스 | A new method for making krill meal |
US20100226977A1 (en) * | 2007-08-29 | 2010-09-09 | Aker Biomarine Asa | Low viscosity phospholipid compositions |
AU2014100741B4 (en) * | 2007-08-29 | 2014-09-11 | Aker Biomarine Antarctic As | Processes and products thereof |
AU2012244229B2 (en) * | 2007-08-29 | 2013-11-21 | Aker Biomarine Antarctic As | A new method for making krill meal |
US8911888B2 (en) | 2007-12-16 | 2014-12-16 | HGST Netherlands B.V. | Three-dimensional magnetic memory with multi-layer data storage layers |
US8586104B2 (en) * | 2008-04-10 | 2013-11-19 | U.S. Nutraceuticals, LLC | Plant derived seed extract rich in essentially fatty acids derived from Salvia hispanica L. seed: composition of matter, manufacturing process and use |
US8829215B2 (en) * | 2008-05-15 | 2014-09-09 | Pronova Biopharma Norge As | Krill oil process |
US9239334B2 (en) * | 2008-09-08 | 2016-01-19 | President And Fellows Of Harvard College | Fatty acid C16: 1N7-palmitoleate a lipokine and biomarker for metabolic status |
KR101024491B1 (en) * | 2008-12-31 | 2011-03-31 | 인성실업(주) | The Method of Extracting Lipids from Marine Animals |
JP2010241710A (en) * | 2009-04-02 | 2010-10-28 | Japan Health Science Foundation | Ace2 activity inducer |
US9925162B2 (en) | 2009-04-09 | 2018-03-27 | The Regents Of The University Of Colorado | Methods and compositions for inducing physiological hypertrophy |
US9399047B2 (en) | 2009-07-23 | 2016-07-26 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using phospholipids and roe extract |
US8481072B2 (en) | 2009-07-23 | 2013-07-09 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain |
US9913810B2 (en) | 2009-07-23 | 2018-03-13 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using phospholipids and astaxanthin |
US8557275B2 (en) | 2009-07-23 | 2013-10-15 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA |
US20130295171A1 (en) | 2009-07-23 | 2013-11-07 | U.S NUTRACEUTICALS, LLC d/b/a Valensa International | Krill oil and reacted astaxanthin composition and associated method |
US9216164B2 (en) | 2009-07-23 | 2015-12-22 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA |
US9238043B2 (en) | 2009-07-23 | 2016-01-19 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using algae based oils |
US9402857B2 (en) | 2009-07-23 | 2016-08-02 | U.S. Nutraceuticals, LLC | Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin |
WO2011060170A1 (en) * | 2009-11-11 | 2011-05-19 | Dynasep Llc | Energy efficient acetone drying method |
WO2011137160A2 (en) | 2010-04-30 | 2011-11-03 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (ldl) per-oxidation in humans |
US9763897B2 (en) | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
US8663704B2 (en) | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
KR20120051458A (en) * | 2010-11-12 | 2012-05-22 | 주식회사 두산 | Method of preparing a composition including astaxanthin and dha- and/or epa-conjugated phosphatidylserine using krill-derived lecithin, and a composition prepared by the method |
CN102485899A (en) * | 2010-12-03 | 2012-06-06 | 张永志 | Method for preparing high quality Antarctic krill oil rich in phosphatidylserine containing polyunsaturated double-bonded fatty acyl |
CN102041166B (en) * | 2011-01-20 | 2012-05-23 | 山东师范大学 | Method for extracting krill oil with high phosphatide content from Antarctic krills |
WO2012103685A1 (en) * | 2011-02-01 | 2012-08-09 | Nippon Suisan Kaisha, Ltd. | Sexual function improving agent |
KR101045258B1 (en) * | 2011-02-11 | 2011-06-30 | 대덕에프알디(주) | Krill oil and method for manufacturing the same |
US20120231087A1 (en) * | 2011-03-07 | 2012-09-13 | Olympic Seafood | Compositions And Methods for Nutritional Supplementation |
US10052352B2 (en) | 2011-06-15 | 2018-08-21 | Stable Solutions Llc | Therapeutic application of parenteral krill oil |
HUE036720T2 (en) * | 2011-06-15 | 2018-07-30 | Stable Solutions Llc | Therapeutic application of parenteral krill oil |
BR112013032410A2 (en) * | 2011-06-24 | 2017-01-17 | Epitogenesis Inc | pharmaceutical compositions comprising a combination of selection vehicles, vitamins, tannins and flavonoids as antigen specific immunomodulators |
US9107891B2 (en) | 2011-06-29 | 2015-08-18 | Nippon Suisan Kaisha, Ltd. | Method for alleviating fear memory |
CN102559371B (en) * | 2012-02-21 | 2013-09-18 | 山东师范大学 | Method for preparing phosphatidylserine-enriched krill oil |
EP3591103A1 (en) | 2012-09-07 | 2020-01-08 | Japan Science and Technology Agency | Guest-compound-enveloping polymer-metal-complex crystal, method for producing same, method for preparing crystal structure analysis sample, and method for determining molecular structure of organic compound |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
CN102899162B (en) * | 2012-10-25 | 2013-12-04 | 山东师范大学 | Technology for preparing euphausia superba oil in low fluorine content |
CN102899164B (en) * | 2012-10-25 | 2015-12-02 | 山东师范大学 | A kind of technique preparing fluoride-free euphausia superba oil |
CN102925284B (en) * | 2012-10-25 | 2014-01-08 | 山东师范大学 | Technique for extracting low-cholesterol-content krill oil from Antarctic krill |
CN102911786B (en) * | 2012-10-25 | 2014-01-08 | 山东师范大学 | Technology for extracting shrimp oil with low fluoride from euphausia superba |
CN102899163B (en) * | 2012-10-25 | 2015-03-25 | 山东师范大学 | Process for extracting fluoride-free shrimp oil from antarctic krill |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
JP6393501B2 (en) * | 2014-04-03 | 2018-09-19 | 太陽化学株式会社 | Flavor improving agent for polyunsaturated fatty acids |
US11382980B2 (en) | 2013-10-08 | 2022-07-12 | Taiyo Kagaku Co., Ltd. | Oil/fat composition containing polyunsaturated fatty acid |
JP2015096488A (en) * | 2013-10-10 | 2015-05-21 | 康二 嘉島 | Method for inhibiting production of advanced glycation endproducts |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
WO2015142702A1 (en) | 2014-03-18 | 2015-09-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using phospholipids and roe extract |
WO2015142707A1 (en) | 2014-03-18 | 2015-09-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using low molecular weight hyaluronic acid and astaxanthin |
WO2015142700A1 (en) | 2014-03-18 | 2015-09-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using phospholipids and astaxanthin |
WO2015142999A1 (en) | 2014-03-19 | 2015-09-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin |
AU2015265623A1 (en) * | 2014-04-30 | 2016-11-10 | Aker Biomarine Antarctic As | Krill oil preparations and their uses |
JP6299689B2 (en) * | 2014-07-24 | 2018-03-28 | 三生医薬株式会社 | Bioabsorption promoter-containing composition |
WO2016069475A1 (en) | 2014-10-27 | 2016-05-06 | Aseko, Inc. | Subcutaneous outpatient management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
US10328105B2 (en) | 2015-05-27 | 2019-06-25 | Rimfrost Technologies As | Flowable concentrated phospholipid krill oil composition |
JP6858751B2 (en) | 2015-08-20 | 2021-04-14 | アセコー インコーポレイテッド | Diabetes Management Therapy Advisor |
CN105341184A (en) * | 2015-10-14 | 2016-02-24 | 中国农业科学院油料作物研究所 | Functional fat composition having effects of preventing cardiovascular and cerebrovascular diseases and diabetes risk factors |
EP4233855A3 (en) * | 2015-12-14 | 2024-01-17 | Société des Produits Nestlé S.A. | Nutritional composition and infant formula for promoting myelination of the brain |
BR112018077350A2 (en) | 2016-06-29 | 2019-04-09 | Machavert Pharmaceuticals Llc | phospholipid compositions |
WO2018083271A1 (en) * | 2016-11-04 | 2018-05-11 | Immd Sp. Zo.O | Inteligent delivery of ingested and absorbed molecules |
JP7309136B2 (en) * | 2017-04-14 | 2023-07-18 | 学校法人帝京大学 | HDL function improving agent and HDL function improving food composition |
WO2019226186A1 (en) | 2018-05-24 | 2019-11-28 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to alleviate joint pain using hyaluronic acid and eggshell membrane components |
JP2019210239A (en) * | 2018-06-02 | 2019-12-12 | 学校法人 岩手医科大学 | Pharmacological use of 8-hydroxyeicosapentaenoic acid |
DE202018105422U1 (en) | 2018-06-21 | 2018-10-19 | U.S. Nutraceuticals, Llc D/B/A Valensa International | A composition for relieving joint pain using hyaluronic acid and egg shell membrane components |
KR102085506B1 (en) * | 2018-07-25 | 2020-03-05 | 이경희 | Composition for hair colorants having anti-irritation effect |
WO2021138742A1 (en) * | 2020-01-10 | 2021-07-15 | Acasti Pharma Inc. | Composition that promote pro-resolving mediators |
KR102451162B1 (en) * | 2020-09-07 | 2022-10-06 | (주)에스디생명공학 | Composition for Anti-Inflammatory, Anti-Wrinkling, Moisturizing, and Skin Cell Regeneration Property Comprising Enzyme Treated Extract of Krill Oil as Active Ingredient |
CN112494499B (en) * | 2020-12-14 | 2022-01-28 | 山东省科学院生物研究所 | Application of marine phospholipid as effective component in preparing medicine for preventing and/or treating heart diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023546A1 (en) * | 1998-10-21 | 2000-04-27 | Universite De Sherbrooke | Method of extracting lipids from marine and aquatic animal tissues |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54119017A (en) * | 1978-03-06 | 1979-09-14 | Taiyo Fishery Co Ltd | Protective agent for hypertensive disease and production |
JPS60153779A (en) | 1984-01-24 | 1985-08-13 | Hohnen Oil Co Ltd | Nutrient-assisting food |
JPS6130527A (en) * | 1984-07-20 | 1986-02-12 | Kao Corp | Thrombolytic agent |
JPS61118318A (en) * | 1984-11-12 | 1986-06-05 | Pola Chem Ind Inc | Composition having improving action on serum lipid |
JPS63295698A (en) * | 1987-05-27 | 1988-12-02 | Showa Denko Kk | Separation and purification of alpha-linolenic acid |
US4843095A (en) * | 1987-08-07 | 1989-06-27 | Century Laboratories, Inc. | Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis |
JPH01137952A (en) * | 1987-11-20 | 1989-05-30 | Nippon Suisan Kaisha Ltd | Health food |
JPH02167055A (en) * | 1988-12-19 | 1990-06-27 | Seiji Nojima | Functional fish-paste product |
JPH03123470A (en) * | 1989-10-05 | 1991-05-27 | Taiyo Fishery Co Ltd | Method for enhancing angiotensin conversion enzyme inhibiting activity in krill |
JP2558050B2 (en) * | 1993-02-18 | 1996-11-27 | イセ食品株式会社 | Chicken feed |
JPH08219A (en) * | 1994-06-15 | 1996-01-09 | Nippon Synthetic Chem Ind Co Ltd:The | Oil composition having improved function |
JP2666179B2 (en) * | 1994-08-10 | 1997-10-22 | 財団法人韓國食品開發研究院 | Antihypertensive health food composition |
JPH09124470A (en) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | Antistress composition |
JP3664814B2 (en) * | 1996-06-26 | 2005-06-29 | 旭化成ケミカルズ株式会社 | Blood lipid improving agent and food additive |
JP3118556B2 (en) * | 1996-09-27 | 2000-12-18 | 中央水産研究所長 | Fish meat emulsified surimi containing high concentration of fats and oils by fish meat water-soluble protein and method for producing the same |
-
2002
- 2002-06-07 AT AT02734945T patent/ATE419858T1/en active
- 2002-06-07 DK DK08164524.4T patent/DK1997498T3/en active
- 2002-06-07 ES ES08164524T patent/ES2386841T3/en not_active Expired - Lifetime
- 2002-06-07 DE DE60230759T patent/DE60230759D1/en not_active Expired - Lifetime
- 2002-06-07 JP JP2003504980A patent/JP5135568B2/en not_active Expired - Lifetime
- 2002-06-07 CN CN201110219831.4A patent/CN102319266B/en not_active Expired - Lifetime
- 2002-06-07 EP EP02734945A patent/EP1406641B1/en not_active Expired - Lifetime
- 2002-06-07 EP EP08164524A patent/EP1997498B1/en not_active Revoked
- 2002-06-07 ES ES02734945T patent/ES2321066T3/en not_active Expired - Lifetime
- 2002-06-07 WO PCT/CA2002/000843 patent/WO2002102394A2/en active Application Filing
- 2002-06-07 AT AT08164524T patent/ATE554779T1/en active
- 2002-06-07 CA CA2449898A patent/CA2449898C/en not_active Expired - Lifetime
- 2002-06-07 PT PT02734945T patent/PT1406641E/en unknown
- 2002-06-07 CN CNA028121813A patent/CN1516592A/en active Pending
- 2002-06-07 DK DK02734945T patent/DK1406641T3/en active
- 2002-06-07 US US10/481,040 patent/US20040241249A1/en not_active Abandoned
-
2003
- 2003-12-16 NO NO20035618A patent/NO332690B1/en not_active IP Right Cessation
-
2006
- 2006-12-18 US US11/640,235 patent/US8057825B2/en not_active Expired - Fee Related
-
2009
- 2009-04-06 CY CY20091100401T patent/CY1108986T1/en unknown
- 2009-05-29 HK HK09104847.8A patent/HK1126957A1/en not_active IP Right Cessation
- 2009-12-04 JP JP2009276479A patent/JP5228185B2/en not_active Expired - Lifetime
- 2009-12-04 JP JP2009276478A patent/JP2010090140A/en active Pending
-
2011
- 2011-08-24 US US13/216,694 patent/US20110305771A1/en not_active Abandoned
-
2012
- 2012-07-04 HK HK12106558.7A patent/HK1165729A1/en not_active IP Right Cessation
-
2013
- 2013-01-08 JP JP2013001424A patent/JP2013079278A/en active Pending
-
2014
- 2014-01-10 US US14/152,603 patent/US20140199414A1/en not_active Abandoned
-
2016
- 2016-09-16 US US15/267,988 patent/US20170224742A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000023546A1 (en) * | 1998-10-21 | 2000-04-27 | Universite De Sherbrooke | Method of extracting lipids from marine and aquatic animal tissues |
Non-Patent Citations (1)
Title |
---|
See also references of EP1406641A2 * |
Cited By (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8383675B2 (en) | 2001-07-27 | 2013-02-26 | Neptune Technologies & Bioressources, Inc. | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
US8680080B2 (en) | 2001-07-27 | 2014-03-25 | Neptune Technologies & Bioressources, Inc. | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
US8278351B2 (en) | 2001-07-27 | 2012-10-02 | Neptune Technologies & Bioressources, Inc. | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
AU2013205515B2 (en) * | 2001-07-27 | 2015-07-02 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
AU2013205514B2 (en) * | 2001-07-27 | 2015-07-02 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising flavonoids, polyunsaturated fatty acids and their applications |
US10028968B2 (en) | 2001-07-27 | 2018-07-24 | Aker Biomarine Antarctic As | Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications |
US10744146B2 (en) | 2001-08-02 | 2020-08-18 | Suntory Holdings Limited | Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction |
WO2004064820A2 (en) * | 2003-01-20 | 2004-08-05 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
WO2004064820A3 (en) * | 2003-01-20 | 2004-09-30 | Tno | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
US8703172B2 (en) | 2003-01-20 | 2014-04-22 | Nederlandse Organizatie voor Toegepastnatuurwetenschappelijk Onderzoek TNO | Sphingolipids for improvement of the composition of the intestinal flora |
US7968529B2 (en) | 2003-01-20 | 2011-06-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels |
WO2004112776A3 (en) * | 2003-06-23 | 2005-03-31 | Advanced Bionutrition Europ Lt | Inflammatory disease treatment |
WO2004112776A2 (en) | 2003-06-23 | 2004-12-29 | Advanced Bionutrition (Europe) Limited | Inflammatory disease treatment |
FR2859380A1 (en) * | 2003-09-05 | 2005-03-11 | Phythea | Orally administered cosmetic skin treatment composition, effective in improving moisturization, texture and suppleness, containing synergistic combination of krill, kiwi fruit seed and cold sea fish oils |
US8052992B2 (en) | 2003-10-22 | 2011-11-08 | Enzymotec Ltd. | Glycerophospholipids containing omega-3 and omega-6 fatty acids and their use in the treatment and improvement of cognitive functions |
US7968112B2 (en) | 2003-10-22 | 2011-06-28 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
KR101249707B1 (en) | 2003-10-28 | 2013-04-05 | 에모리 유니버시티 | Dialysates and methods and systems related thereto |
JP2005132758A (en) * | 2003-10-29 | 2005-05-26 | Suntory Ltd | Composition having preventing or ameliorating action on symptom or disease caused by blood vessel aging |
AU2004283610B2 (en) * | 2003-10-29 | 2011-02-03 | Suntory Holdings Limited | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
WO2005039559A1 (en) * | 2003-10-29 | 2005-05-06 | Suntory Limited | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
KR101245364B1 (en) * | 2003-10-29 | 2013-03-19 | 산토리 홀딩스 가부시키가이샤 | Composition functioning to prevent or mitigate symptom or disease attributable to blood vessel aging |
EP1727882A4 (en) * | 2004-02-06 | 2008-12-10 | Adrien Beaudoin | Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof |
EP1727882A1 (en) * | 2004-02-06 | 2006-12-06 | Adrien Beaudoin | Method for preventing the oxidation of lipids in animal and vegetable oils and compositions produced by the method thereof |
JP2007529507A (en) * | 2004-03-16 | 2007-10-25 | ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | Methods of using sphingolipids in the treatment and prevention of type 2 diabetes, insulin resistance and metabolic syndrome |
US8202907B2 (en) | 2004-09-17 | 2012-06-19 | Suntory Holdings Limited | Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders |
US8367729B2 (en) | 2004-09-17 | 2013-02-05 | Suntory Holdings Limited | Composition with preventive or improvement effect on symptoms or diseases associated with stress-induced behavior disorders |
US7666447B2 (en) | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
US7906488B2 (en) | 2004-11-30 | 2011-03-15 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
EP1736149A3 (en) * | 2005-06-23 | 2007-02-21 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin-containing agent for lowering neutral fat concentration in blood |
US9168241B2 (en) | 2005-06-30 | 2015-10-27 | Suntory Holdings Limited | Compositions ameliorating a reduced diurnal activity and/or depressive symptoms |
WO2007045407A3 (en) * | 2005-10-18 | 2007-07-26 | Artmed S R L | Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma |
WO2007045407A2 (en) * | 2005-10-18 | 2007-04-26 | Artmed S.R.L. | Nutraceutical and pharmaceutical compositions containing choline as adiuvants for the prevention and treatment of retinopathies and glaucoma |
WO2007080515A1 (en) * | 2006-01-13 | 2007-07-19 | Aker Biomarine Asa | Thrombosis preventing krill extract |
WO2008139261A3 (en) * | 2006-11-03 | 2009-08-20 | Pronova Biopharma Norge As | Omega-3 lipid compound |
WO2008139261A2 (en) * | 2006-11-03 | 2008-11-20 | Pronova Biopharma Norge As | Omega-3 lipid compound |
US8383677B2 (en) | 2006-12-28 | 2013-02-26 | Suntory Holdings Limited | Nerve-regenerating agent |
AU2014100740B4 (en) * | 2007-03-28 | 2014-11-20 | Aker Biomarine Antarctic As | Processes and products thereof |
US9644169B2 (en) | 2007-03-28 | 2017-05-09 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US11865143B2 (en) | 2007-03-28 | 2024-01-09 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
WO2008117062A1 (en) * | 2007-03-28 | 2008-10-02 | Aker Biomarine Asa | Bioeffective krill oil compositions |
AU2011213836B2 (en) * | 2007-03-28 | 2013-11-14 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US10543237B2 (en) | 2007-03-28 | 2020-01-28 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US10010567B2 (en) | 2007-03-28 | 2018-07-03 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US9889163B2 (en) | 2007-03-28 | 2018-02-13 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US9816046B2 (en) | 2007-03-28 | 2017-11-14 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US8697138B2 (en) | 2007-03-28 | 2014-04-15 | Aker Biomarine As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
US9730966B2 (en) | 2007-03-28 | 2017-08-15 | Aker Biomarine Antartic As | Method of reducing appetite in a human subject comprising administering krill oil composition |
EP2612672A1 (en) | 2007-03-28 | 2013-07-10 | Aker BioMarine AS | Bioeffective krill oil compositions |
AU2014100736B4 (en) * | 2007-03-28 | 2014-09-18 | Aker Biomarine Antarctic As | Processes and products thereof |
US9644170B2 (en) | 2007-03-28 | 2017-05-09 | Aker Biomarine Antarctic As | Bioeffective krill oil compositions |
US9220735B2 (en) | 2007-03-28 | 2015-12-29 | Aker Biomarine Antarctic As | Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders |
AU2008231570C1 (en) * | 2007-03-28 | 2014-11-27 | Aker Biomarine Human Ingredients As | Bioeffective krill oil compositions |
AU2014100739B4 (en) * | 2007-03-28 | 2014-11-20 | Aker Biomarine Antarctic As | Processes and products thereof |
AU2008231570B2 (en) * | 2007-03-28 | 2011-10-13 | Aker Biomarine Human Ingredients As | Bioeffective krill oil compositions |
US9167832B2 (en) | 2008-09-12 | 2015-10-27 | Emerald Fisheries As | Low flouride crustacean concentrated hydrolysate fraction compositions |
US8557297B2 (en) | 2008-09-12 | 2013-10-15 | Olympic Seafood, As | Method for processing crustaceans and products thereof |
US10701954B2 (en) | 2008-09-12 | 2020-07-07 | Rimfrost Technologies As | Reduced fluorine crustacean polar phospholipid compositions |
US10499673B2 (en) | 2008-09-12 | 2019-12-10 | Rimfrost Technologies As | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
US9907321B2 (en) | 2008-09-12 | 2018-03-06 | Rimfrost Technologies As | Separating crustacean polar phospholipid compositions without emulsification |
US9068142B2 (en) | 2008-09-12 | 2015-06-30 | Olympic Seafood As | Reduced fluoride crustacean oil compositions |
US9480273B2 (en) | 2008-09-12 | 2016-11-01 | Rimfrost As | Reduced flouride crustacean de-oiled protein-phospholipid complex compositions |
US8372812B2 (en) | 2009-02-26 | 2013-02-12 | Aker Biomarine Asa | Phospholipid and protein tablets |
WO2010136900A2 (en) | 2009-05-28 | 2010-12-02 | Aker Biomarine Asa | Methods of using krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders |
WO2010136900A3 (en) * | 2009-05-28 | 2011-06-16 | Aker Biomarine Asa | Methods of using krill oil to treat risk factors for metabolic disorders and obesity |
EP3335713A1 (en) * | 2009-10-29 | 2018-06-20 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
KR101788342B1 (en) * | 2009-10-29 | 2017-10-19 | 아카스티 파마, 인크. | Concentrated therapeutic phospholipid compositions |
CN102753182B (en) * | 2009-10-29 | 2014-10-29 | 阿卡斯蒂制药股份有限公司 | concentrated therapeutic phospholipid compositions |
US10130644B2 (en) | 2009-10-29 | 2018-11-20 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
US9475830B2 (en) | 2009-10-29 | 2016-10-25 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
WO2011050474A1 (en) | 2009-10-29 | 2011-05-05 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
US8586567B2 (en) | 2009-10-29 | 2013-11-19 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
CN102753182A (en) * | 2009-10-29 | 2012-10-24 | 阿卡斯蒂制药股份有限公司 | Concentrated therapeutic phospholipid compositions |
US10617702B2 (en) | 2009-10-29 | 2020-04-14 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
US8772516B2 (en) | 2009-10-30 | 2014-07-08 | Tharos. Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
US9150815B2 (en) | 2009-10-30 | 2015-10-06 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
US8865236B2 (en) | 2009-10-30 | 2014-10-21 | Tharos Ltd. | Solvent-Free Process for Obtaining Phospholipids and Neutral Enriched Krill Oils |
US8609157B2 (en) | 2009-10-30 | 2013-12-17 | Tharos Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
US9011942B2 (en) | 2009-10-30 | 2015-04-21 | Tharos, Ltd. | Solvent-free process for obtaining phospholipids and neutral enriched krill oils |
WO2011062953A1 (en) * | 2009-11-17 | 2011-05-26 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Use of eggshell membrane formulations to alleviate joint pain |
US8691297B2 (en) | 2010-09-01 | 2014-04-08 | Nippon Suisan Kaisha, Ltd. | Alcoholic injury mitigating agent |
US9061035B2 (en) | 2010-09-01 | 2015-06-23 | Nippon Suisan Kaisha, Ltd. | Alcoholic injury mitigating agent |
US8846604B2 (en) | 2011-09-02 | 2014-09-30 | Artic Nutrition AS | Lipid compositions with high DHA content |
US11135230B2 (en) | 2011-09-02 | 2021-10-05 | Arctic Nutrition As | Lipid compositions with high DHA content |
US9458409B2 (en) | 2011-09-02 | 2016-10-04 | Arctic Nutrition As | Lipid compositions with high DHA content |
US10076530B2 (en) | 2011-09-02 | 2018-09-18 | Arctic Nutrition As | Lipid compositions with high DHA content |
WO2013102792A2 (en) | 2012-01-03 | 2013-07-11 | Olympic Seafood As | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
EP3311679A1 (en) | 2012-01-03 | 2018-04-25 | Rimfrost Technologies AS | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
EP4005395A2 (en) | 2012-01-03 | 2022-06-01 | Rimfrost Technologies AS | Method for processing crustaceans to produce low fluoride/low trimethyl amine products thereof |
US10117844B2 (en) | 2012-01-06 | 2018-11-06 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9050309B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9050308B2 (en) | 2012-01-06 | 2015-06-09 | Omthera Pharmaceuticals, Inc. | DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form |
US9492545B2 (en) | 2012-05-07 | 2016-11-15 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
WO2014184655A1 (en) | 2013-02-07 | 2014-11-20 | Olympic Seafood As | Methods for using crustacean phospholipid-peptide-protein complexes |
US11578289B2 (en) | 2013-06-14 | 2023-02-14 | Aker Biomarine Antarctic As | Lipid extraction processes |
US10704011B2 (en) | 2013-06-14 | 2020-07-07 | Aker Biomarine Antarctic As | Lipid extraction processes |
US9867856B2 (en) | 2014-01-10 | 2018-01-16 | Aker Biomarine Antarctic As | Phospholipid compositions and their preparation |
US10456412B2 (en) | 2015-02-11 | 2019-10-29 | Aker Biomarine Antarctic As | Lipid extraction processes |
US10864223B2 (en) | 2015-02-11 | 2020-12-15 | Aker Biomarine Antarctic As | Lipid compositions |
US11819509B2 (en) | 2015-02-11 | 2023-11-21 | Aker Biomarine Antarctic As | Lipid compositions |
EP3181129A1 (en) * | 2015-12-15 | 2017-06-21 | Wolfgang Braun | Composition for the treatment of premenstrual syndrome |
US11654163B2 (en) | 2017-12-22 | 2023-05-23 | Pharmalink International Limited | Lipid combinations |
US20220265291A9 (en) * | 2018-06-28 | 2022-08-25 | Marizyme, Inc. | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
WO2020006444A1 (en) * | 2018-06-28 | 2020-01-02 | Marizyme Biotech | Pharmaceutical compositions and methods for the treatment of thrombosis and delivery by medical devices |
WO2021170548A1 (en) * | 2020-02-26 | 2021-09-02 | Umberto Cornelli | Pharmaceutical composition for use in the treatment of dysmenorrhea and/or premenstrual syndrome (pms) |
IT202000003964A1 (en) * | 2020-02-26 | 2021-08-26 | Umberto Cornelli | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DYSMENORREA AND / OR PREMESTRUAL SYNDROME |
CN112315984B (en) * | 2020-09-09 | 2023-02-14 | 山东省科学院生物研究所 | Application of marine-derived phospholipid in promoting angiogenesis |
CN112315984A (en) * | 2020-09-09 | 2021-02-05 | 山东省科学院生物研究所 | Application of marine-derived phospholipid in promoting angiogenesis |
GB2612442A (en) * | 2021-09-28 | 2023-05-03 | L Shepherd Samuel | Tetraterpenes for use in cancer therapy |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8057825B2 (en) | Krill extracts for treatment of cardiovascular diseases | |
EP1871399B1 (en) | Use of lecithin as a medicament for treating psoriasis | |
EP1337263B1 (en) | A composition of rose hip and fish oil for alleviating joint pain and stiffness | |
US20030166614A1 (en) | Method for reducing cholesterol and triglycerides | |
Smith et al. | Complementary and alternative medicine for psoriasis: a qualitative review of the clinical trial literature | |
EP0440341A1 (en) | EFA compositions and therapy | |
ZA200700694B (en) | Compositions and methods for the management of hyperproliferative dermatological conditions | |
JPH04290822A (en) | Allergy preventing medicine and food | |
CA2024724A1 (en) | Fatty acid therapy | |
JPS6218A (en) | Composition for treating dermatopathy | |
US20040091506A1 (en) | Topical antifungal treatment | |
US10517838B2 (en) | Compositions against alkyl-acyl GPC, the derivatives and products thereof | |
US20170135930A1 (en) | Cosmetic, dermatic, protective compositions comprising phospholipids, lecithins with peptides and at least one acetylating compound. | |
HU227182B1 (en) | Lecitin-ascorbic acid combination | |
Lieberman | Natural Interventions for Treating Psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2449898 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003504980 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028121813 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002734945 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002734945 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10481040 Country of ref document: US |